Compare ONON & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONON | NBIX |
|---|---|---|
| Founded | 2010 | 1992 |
| Country | Switzerland | United States |
| Employees | N/A | 2000 |
| Industry | Shoe Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3B | 13.2B |
| IPO Year | 2021 | 1996 |
| Metric | ONON | NBIX |
|---|---|---|
| Price | $34.69 | $132.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 21 | 22 |
| Target Price | $60.14 | ★ $175.27 |
| AVG Volume (30 Days) | ★ 7.7M | 810.0K |
| Earning Date | 03-03-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | N/A | ★ 4.67 |
| Revenue | N/A | ★ $161,626,000.00 |
| Revenue This Year | $19.24 | $22.85 |
| Revenue Next Year | $19.81 | $10.36 |
| P/E Ratio | $56.05 | ★ $28.20 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $31.41 | $84.23 |
| 52 Week High | $61.29 | $160.18 |
| Indicator | ONON | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 36.80 | 54.02 |
| Support Level | $34.38 | $128.03 |
| Resistance Level | $44.10 | $136.74 |
| Average True Range (ATR) | 1.61 | 3.27 |
| MACD | -0.35 | 0.47 |
| Stochastic Oscillator | 35.79 | 80.18 |
On Holding AG is a premium performance sports brand rooted in technology, design, and impact. Its shoes, apparel, and accessories products are designed predominantly for athletic use, casual, or leisure purposes. It does not manufacture the products or the raw materials and relies instead on third-party suppliers and contract manufacturers. Geographically, it derives a majority of its revenue from the Americas and rest from Europe, Middle East and Africa and Asia-Pacific region.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.